ABL1 and cerebrovascular disorder: In this study, we aimed to evaluate the 5-year incidence and compare the ratios of significant cardiovascular outcomes in patients with CML without a past history of heart or cerebrovascular diseases treated with Bcr-ABL TKIs imatinib, dasatinib, or nilotinib, using data from a large multinational network based on electronic medical records.